Haemophilia
0
Pipeline Programs
2
Companies
5
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
PfizerNEW YORK, NY
3 programsAdherence to Treatment in HemophiliaN/A1 trial
Psychology and Physiotherapy groupN/A1 trial
Trainings applicationN/A1 trial
Active Trials
Novo NordiskBAGSVAERD DENMARK, Denmark
2 programsCombining Registry Data in Haemophilia: TARGET HN/A1 trial
No treatment givenN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Novo NordiskNo treatment given
PfizerPsychology and Physiotherapy group
PfizerTrainings application
PfizerAdherence to Treatment in Hemophilia
Novo NordiskCombining Registry Data in Haemophilia: TARGET H
Clinical Trials (5)
Total enrollment: 583 patients across 5 trials
Defeat Rare Disease in Asia and Pacific (APAC) DRDA - Haemophilia
Start: Jan 2025Est. completion: Dec 2025244 patients
N/AEnrolling By Invitation
Psychology and Physiotherapy Approach of Chronic Pain in Patients With Hemophilia
Start: Mar 2018Est. completion: Mar 201919 patients
N/ACompleted
iT-based Sports Therapy Application in Haemophilia
Start: Jan 2018Est. completion: Dec 202120 patients
N/ACompleted
Adherence to Treatment in Hemophilia
Start: May 2015Est. completion: Feb 2016200 patients
N/AUnknown
Combining Registry Data in Haemophilia: TARGET H
Start: May 2015Est. completion: Sep 2015100 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space